Experimental COVID-19 drug shows promise in tiny trial
NCT ID NCT04534673
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether adding pegylated interferon lambda to standard care helps hospitalized adults with mild-to-moderate COVID-19 recover faster. Nine participants were randomly assigned to receive the drug or standard care alone. The study measured how long the virus remained detectable and how quickly symptoms improved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pegylated interferon lambda
What this could lead to
If it works, this could point toward a treatment that shortens COVID-19 symptoms and reduces the need for breathing support.
What could go wrong
This is a very small pilot trial with only 9 participants, so results may not apply to the general population. The drug may not speed recovery or reduce complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Soroka UMC
Beersheba, Israel